We are pleased to announce that SUNOVION’s recent peer to peer education efforts in the Long-Term Care (LTC) industry has been recognized by the National Association of Directors of Nursing Administration (NADONA). Sunovion was honored twice with an Award of Excellence in LTC by the NADONA. Sunovion was awarded from TXADONA in San Marcos, TX and from the 2015 NADONA Board during the NADONA 2015 National Conference in Atlanta on June 9, 2015.

This award recognizes the commitment of Sunovion as being a leader in the long term care industry. Sunovion has fulfilled on a promise of education and awareness to improve the quality of life of residents in the LTC setting. As a result of Sunovion’s high level of engagement and support at the National Conference, Sunovion was invited to attend the Awards Banquet dinner on June 9, 2015.  Thom Whitledge, Corporate Account Director, was invited up on stage and was presented with a plaque inscribed in part as follows: “NADONA LTC Together, We Can.  Through Teamwork, All Things Are Possible Sunovion Pharmaceuticals.” This award showcases the importance of pharmaceutical industry-advocacy group cooperation to enhance options for LTC residents. We know that this is only the beginning of a long-standing relationship to “make a difference through teamwork.” Thom Whitledge was joined by the President and Chairman of the Board of Directors for formal pictures to commemorate the award. The photo will be printed in an upcoming issue of NADONA’s publication, The Director.

AXON Communications (axon-com.com), has supported Aptiom and Brovana with medical communication initiatives for SUNOVION to enhance the partnership with NADONA.  This recent partnership has allowed SUNOVION to educate LTC professionals on the value of adjunctive therapy for epilepsy, such as Aptiom®, for residents who suffer from partial-onset seizures and the benefits of nebulized therapy, such as Brovana®, for their residents with chronic obstructive pulmonary disease (COPD).

About Partial-Onset Seizures
Epilepsy is characterized by abnormal firing of impulses from nerve cells in the brain. In partial-onset seizures, these bursts of electrical activity are initially focused in specific areas of the brain, but may -become more widespread, with symptoms varying according to the affected areas. The unpredictable nature of seizures can have a significant impact on those with epilepsy, affecting a number of areas of daily living, including education, employment, driving and recreation. Reducing the frequency of seizures can greatly lessen the burden of epilepsy. With approximately one-third of people living with epilepsy still unable to control seizures, there continues to be a need for new therapies.

About Aptiom® (eslicarbazepine acetate)
APTIOM, a voltage-gated sodium channel inhibitor, is a once-daily prescription medicine approved for use as adjunctive treatment of partial-onset seizures, and is available in four tablet strengths (200 mg, 400 mg, 600 mg, and 800 mg), which can be taken whole or crushed, with or without food. APTIOM is not classified as a controlled substance by the FDA.

The initial research and development of eslicarbazepine acetate was performed by BIAL-Portela & Ca, S.A. (BIAL), a privately held Portuguese research-based pharmaceutical company. Subsequently, Sunovion acquired the rights under an exclusive license to further develop and commercialize eslicarbazepine acetate in the United States and Canadian markets from BIAL. BIAL gained approval for eslicarbazepine acetate from the European Commission on April 21, 2009 as adjunctive therapy in adult patients with partial-onset seizures with or without secondary generalization.

About Brovana® (arformoterol tartrate) Inhalation Solution
Brovana® (arformoterol tartrate) Inhalation Solution is indicated for the long-term, twice-daily (morning and evening) maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. BROVANA is for use by nebulization only.

About Sunovion Pharmaceuticals Inc. (Sunovion)
Sunovion is a leading pharmaceutical company dedicated to discovering, developing and commercializing therapeutic products that advance the science of medicine in the Psychiatry, Neurology and Respiratory disease areas to improve the lives of patients and their families.

Sunovion, an indirect, wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is headquartered in Marlborough, Mass. More information about Sunovion Pharmaceuticals Inc. is available at www.sunovion.com.

About Sumitomo Dainippon Pharma Co., Ltd.
Sumitomo Dainippon Pharma is a top-ten listed pharmaceutical company in Japan with a diverse portfolio of pharmaceutical, animal health and food and specialty products. Sumitomo Dainippon Pharma aims to produce innovative pharmaceutical products in the Psychiatry & Neurology area and the Oncology area, which have been designated as the focus therapeutic areas. Sumitomo Dainippon Pharma is based on the merger in 2005 between Dainippon Pharmaceutical Co., Ltd., and Sumitomo Pharmaceuticals Co., Ltd. Today, Sumitomo Dainippon Pharma has about 7,000 employees worldwide. Additional information about Sumitomo Dainippon Pharma is available through its corporate website at www.ds-pharma.com.